Hyper-immunoglobulin M syndrome is an X-linked primary immunodeficiency disease caused by mutations in the CD40 ligand gene. The CD40 ligand has been recently highlighted as playing a key role in the pathogenesis of primary biliary cholangitis. In the present study, we assessed an extensive set of serum autoantibodies in a series of well-defined patients with hyper-immunoglobulin M syndrome. Serum, liver-related and liver-not-related autoantibodies IgG, IgM and IgA were tested by ELISA and standard indirect immunofluorescence in HEp-2 cells in 13 Tunisian patients (8 males and 5 females, aged 1-12 years) with hyper-immunoglobulin M syndrome during 1995-2012 and, as controls, 21 age-and gender-matched blood donors. The level of IgM antibody against MIT3 was significantly higher in patients than in controls (35.8 vs 10.7, P = 0.002). Half of the hyperimmunoglobulin M syndrome patients were found to be anti-MIT3 IgM positive vs none of the controls (Po0.0001). Twenty-three percent of patients were found to be anti-sp100 antibody positive vs only 0.05% of controls. By immunofluorescence, 92.3% of patients were MIT3 IgM positive vs none of the controls. In conclusion, the IgM class of anti-MIT3 antibodies was shown to be present by both ELISA and immunofluorescence in most of the patients with hyper-immunoglobulin M syndrome. The presence of the hallmark of primary biliary cholangitis, a disease where the CD40 ligand is a key player, in an immunodeficiency disease caused by mutations in the CD40 ligand gene is very intriguing and opens new scenarios in understanding the immune pathogenesis of primary biliary cholangitis.
INTRODUCTION
Immunoglobulin M (IgM) is the first antibody to be produced by mature B cells and plasma cells during an immune response after an initial antigen encounter. It is the predominant isotype secreted in T-cell-independent immune responses. 1 Although the existence of IgM has been known for several decades, its biological significance in immunity and autoimmunity continues to emerge. IgM plays an important regulatory role in the subsequent development of immune responses against foreign pathogens and self-antigens by accelerating the production of high-affinity IgG. The process controlling B-cell maturation and immunoglobulin isotype switching is largely regulated by the cross-talk between CD40 and CD40L.
Hyper-immunoglobulin M (HIGM) syndrome is a rare form of X-linked primary immunodeficiency disease (PIDD) caused by mutations in the gene that encodes the CD40 ligand 4 Autoimmunity has been described in all forms of HIGM syndrome, with variable presentation and immunological and clinical phenotype. 5 In a somewhat paradoxical manner, the susceptibility to opportunistic and bacterial infections seen in HIGM patients is accompanied by a vulnerability to develop autoimmune diseases such as immune thrombocytopenia, Coombs-positive hemolytic anemia and nephritis, suggesting that tolerance is not correctly maintained in these patients. 5 It has been reported that the sera from CD40L-deficient patients contain specific antibodies against self-antigens (anti-erythrocyte, anti-erythropoietin, anti-platelet, anti-smooth muscle, anti-cardiolipin, anti-Ro, anti-RNP, anti-nuclear and antithyroid). 6, 7 Other autoimmune manifestations seen in HIGM patients include inflammatory bowel disease, autoimmune hepatitis, seronegative arthritis, hypothyroidism and discoid lupus erythematosus. 8 It appears that most patients with HIGM also develop some form of autoimmune disease, particularly those with HIGM due to intrinsic B-cell deficiencies. 9 Although the first description of HIGM syndrome cases dates to the 1960s, there has been no systematic evaluation of either the prevalence or spectrum of antibodies to common autoantigens in this disorder. In the present study, we performed an extensive assessment of serum autoantibodies in a series of well-defined patients with HIGM syndrome. (Table 2 ). These control individuals had undergone minor surgery for orthopedic, non-infectious conditions. The sera were analyzed for basic chemistry and liver panels, including AST, ALT, ALP, GGT, total and direct bilirubin, and baseline IgG, IgA and IgM levels.
MATERIALS AND METHODS
Detection of autoantibody repertoires by ELISA Serum autoantibody screening was performed in a blinded fashion at a 1:101 dilution using commercially available FDAcleared ELISA kits (QUANTA Lite ® ; Inova Diagnostics, Inc., San Diego, CA, USA) for IgG antibodies against M2 EP (MIT3), gp210, sp100, f-actin, SLA, LKM-1, TPO, ATG, GPA, MPO and anti-centromere. To detect IgA and IgM antibodies against M2 EP (MIT3), gp210, and sp100, QUANTA Lite ELISA plates and anti-peroxidase-conjugated goat anti-human immunoglobulin IgA or IgM were used to perform an in-house research assay. No manufacturer-supplied controls were used in these assays. Briefly, 100 μl of 1:101-diluted serum was added to polystyrene microwells coated with the respective antigen. The samples were run in duplicate, and the reactions were allowed to proceed for 30 min at room temperature. After washing three times, 100 μl of peroxidaseconjugated goat anti-human immunoglobulin IgG, IgA or IgM was added to each well, followed by incubation for 30 min. Following washing, 100 μl of 3,3, 5,5′-tetramethylbenzidine chromogen was added to the wells, which were then incubated for 30 min, followed by the addition of 100 μl of 0.344 M H 2 SO 4 stop solution to terminate the reaction. The absorbance was read at 450/620 nm, and the results, expressed in arbitrary units, were calculated in reference to a kit-provided calibrator for the IgG assays. The manufacturer's cutoff was established at 25 units depending on the specific assay. San Diego, CA, USA). Briefly, reactivities were analyzed by serial dilutions in phosphate-buffered saline (PBS) on human epithelial cell (HEp-2 cell)-fixed slides in a moist chamber at room temperature for 30 min. After washing with PBS, the slides were incubated with fluorescent antibody conjugate (fluorescein isothiocyanate-labeled goat anti-human immunoglobulin) in a moist chamber at room temperature for 30 min. Immunofluorescent images were acquired using fixed exposure times and enhancement parameters using a × 40 objective and an Olympus BX51 fluorescence microscope (Olympus America, Inc., NY, USA).
Statistical analysis
An optimized cutoff for the detection of the IgA and IgM antibodies for the three antigens MIT3, sp100 and gp210 was calculated using the formula 'mean OD of matched controls+3 s.d.'. This value was referenced as 25 units, and relative unit values were calculated based on this cutoff. The data were analyzed by the Kruskal-Wallis H test and χ 2 -test; the coincidence of two tests was compared using the Kappa index. Two-tailed P values o0.05 were considered statistically significant. Scattergrams were plotted using GraphPad Prism (GraphPad Software, Inc., San Diego, CA, USA).
RESULTS

Patient characteristics
Thirteen patients (8 male and 5 female, aged 1-12 years) were identified as having HIGM based on a hyper-IgM screen to detect high levels of IgM and low or absent levels of IgA and IgG. The clinical features, abnormal biochemistry parameters and serum autoantibody repertoires of the enrolled cases are summarized in Table 1 . Four patients had a family history of immunodeficiency. Patient 1 (P1) and P2 are cousins, while the sister of P1 was also diagnosed with HIGM and died of Hodgkin's lymphoma. In addition, P4 and P5 are brothers. Gene mutations were found in 8 of 13 patients (61.54%), in which 5 patients showed a mutation in the AID or C terminal end of the AID Gene, 1 patient had a mutation in the CD40 ligand gene, and 2 patients had an ATM gene mutation.
Clinical presentations
All patients experienced chronic and recurrent infections, particularly recurrent ear, nose and throat (ENT) infections involving the respiratory and gastrointestinal systems, during the course of the disease. These HIGM patients presented with various forms of infections (Table 3) , with ENT being the most common (53.85%), followed by recurrent pneumonias and bronchopneumopathies (38.46%). Protracted or recurrent diarrhea was present in four patients (30.77%). Oral thrush due to candidiasis was observed in three patients (23.08%). Moreover, three patients (23.08%) developed adenopathy. Two patients developed episodes of chronic otitis, with one developing permanent hearing loss. Of note, two patients (P1 and P2) developed ataxia-telangiectasia during follow-up.
Laboratory findings
The biochemical and immunological profiles of the HIGM patients and controls are presented in Conversely, the levels of IgG and IgA in the HIGM patient group were significantly lower than those in the control group (P = 0.007 and P = 0.001, respectively). The levels of AST, total bilirubin and direct bilirubin in HIGM patients were statistically lower than those in controls; however, the levels of these parameters in both groups were all within the normal range. Regarding the remaining biochemical parameters, there were no significant differences between patients with HIGM and controls.
Autoantibody repertoires
The autoantibody profiles of HIGM patients and controls are presented in Table 4 and Figure 1 . When PBC autoantibodies were measured, it was found that the level of IgM antibody against MIT3 was significantly higher in HIGM patients than in controls (P = 0.002). By contrast, the levels of both IgG and IgA against MIT3 were significantly lower in HIGM patients than in controls (P = 0.002 and Po0.0001, respectively). In addition, both IgG and IgA autoantibodies against sp100 or gp210 were also significantly lower in the HIGM cohorts than in the controls (P = 0.0001 and P = 0.018; P = 0.004 and P = 0.004, respectively). Similarly, HIGM patients also had lower IgG autoantibody levels against f-actin than the controls (P = 0.032). However, there were no statistical differences in the IgG levels of other autoimmune liver diseases-related autoantibodies, including anti-SLA and anti-LKM1. Regarding extrahepatic autoantibodies, there was no significant difference in the levels of ANA, anti-SS-A and SS-B, anti-centromere, anti-Sm, anti-Scl-70, anti-MPO, anti-TPO, anti-Thyroid T, and anti-GPA autoantibodies between the two groups. Furthermore, we set out to evaluate the prevalence of the PBC-specific autoantibody IgM class in HIGM patients and controls. With the cutoff value at 25 units, 7/13 HIGM patients (53.84%) were found to be anti-MIT3 IgM positive, whereas none of the controls were found to be positive (Po0.00). Regarding anti-sp100 autoantibodies, 3/13(23.08%) HIGM patients were found to have anti-sp100 IgM autoantibodies, while only 1/21 controls (0.05%) were positive for anti-sp100 IgM autoantibodies (P40.05). Additionally, 1/13 (7.69%) HIGM patients were positive for anti-gp210 IgM antibodies, while no control was found to be positive for anti-gp210 IgM class (P40.05).
To further confirm our finding that HIGM children had higher IgM antibodies against MIT3, we also analyzed autoantibodies against AMA by immunofluorescence. Twelve patients (92.31%) were found to be positive for AMA IgM (titer 1/40, n = 2; 1/80, n = 1; 1/160, n = 3; 1/320, n = 1; 1/640, n = 1; 1/1280, n = 3; 1/2560, n = 3). Conversely, none of the controls (0%) were found to be positive by immunofluorescence (Po0.001). In addition, no HIGM or control was found to be positive for the AMA IgA and IgG isotypes. Moreover, sera from HIGM patients showed a representative IIF pattern in HEP-2 cells similar to that seen for typical PBC patients. For example, some HIGM patients presented with cytoplasmic and a smooth nuclear rim-staining pattern, while some presented with a nuclear dot staining pattern (Figures 2a and b) . Additionally, some patients had both the smooth nuclear rim-staining and nuclear dot-staining patterns (Figure 2c ).
DISCUSSION
HIGM syndrome is the prototypic disorder of immunodeficiency caused by genetic defects in the CD40-CD40L pathway or enzymes required for immunoglobulin class-switch recombination and somatic hypermutation. 10, 11 Thus, patients with HIGM have an increased susceptibility to opportunistic infections, neutropenia, autoimmune disease and cancer, particularly of the liver or biliary tree. 12 Affected patients frequently present with sclerosing cholangitis (due to Cryptosporidium parvum infections), chronic hepatitis (related to hepatitis B virus, hepatitis C virus and cytomegalovirus), and liver and biliary tract tumors. 9 Interestingly, several studies have reported that HIGM patients are prone to developing autoimmune diseases such as Coombs-positive hemolytic anemia, Crohn's disease, type 1 diabetes mellitus, immune thrombocytopenia and nephritis, suggesting that immune tolerance is not correctly maintained in HIGM. 9, 13 Because the liver is a unique lymphoid organ that plays a significant role in immune homeostasis, it is quite possible that autoimmune liver diseases may be a part of the spectrum of HIGM pathology. A previous report had described that one HIGM patient developed autoimmune hepatitis with several typical autoantibodies of the IgM isotype, including anti-liver-kidney-microsome (LKM), anti-hepatocyte membrane and anti-smooth muscle antibodies. 13 However, in patients with HIGM syndrome, the prevalence of antibodies against autoantigens that are common in other autoimmune disorders, particularly autoimmune liver diseases, has never been systematically assessed.
In the present study, we first comprehensively analyzed the antibody repertoires of HIGM patients compared with those of controls. Second, we dissected in detail the PBC-specific autoantibodies covering IgG, IgA and IgM isotypes using semi-quantitative ELISA. Strikingly, the level of MIT3 IgM antibodies in HIGM patients was significantly higher than that in controls. Moreover, our IIF results further confirmed the high incidence of IgM autoantibodies against MIT3 in this cohort of HIGM patients. Finally, representative IIF patterns for reactivity to HEP-2 cells, similar to typical PBC patients, were noted in these HIGM children.
Our data demonstrated no differences in the prevalence of autoantibodies for a broad spectrum of autoimmune diseases (including systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, microscopic polyangiitis, Graves' disease, and Hashimoto's thyroiditis) between HIGM children and a group of matched controls. Moreover, upon probing for liverspecific autoantibody profiles, HIGM patients demonstrated a negative AIH-specific autoantibody pattern (anti-LKM-1, anti-SLA and anti-f-actin). On the other hand, elevated levels of IgM antibodies were observed in our HIGM cohorts compared with those in contemporary controls by our MIT3-based ELISA. The MIT3 ELISA utilizes the immunodominant targets of AMA (PDC-E2, OGDC-E2 and BCOADC-E2) and has been shown to have enhanced performance with well-balanced specificity and sensitivity. 14, 15 Consistent results were obtained, showing that most of the HIGM children showed positive AMA reactivity at high titers (41/40) by IIF. AMA is the hallmark of PBC, an autoimmune cholestatic liver disease characterized by immune-mediated destruction of small intrahepatic bile ducts with portal inflammation. 16, 17 Notably, the prevalence of anti-sp100 IgM antibodies in our HIGM cohort was much higher than that in controls. In addition to AMA, anti-sp100 autoantibody is also an important complementary biomarker for the diagnosis of PBC, with also a prognostic role. 18 Although the prevalence and, possibly, the incidence of PBC are increasing worldwide, middle-aged females are still the most susceptible demographic for PBC. 19 Unlike other autoimmune liver diseases, such as AIH, few PBC cases had been reported in childhood. 20 However, these HIGM children identified with AMA-positive IgM antibodies have not shown any manifestation of liver injury or bile duct damage (for example, abnormal liver function tests). Because the presence of AMA can precede the development of symptomatic disease, some PBC patients tend to have a long latency period before the onset of clinical symptoms or signs such as cholestasis. 21 PBC is generally a slowly progressive disease. Hence, close follow-up of these children with AMA autoantibodies is essential to improve our understanding of the relationship between autoimmunity and HIGM, as is close monitoring so that the disease can be treated appropriately should any of these children develop PBC in the future.
It is well known that IgM responses play an essential role in innate immunity by providing a first line of host defense against microbial infections. Moreover, IgM has been proposed as an important link between innate and acquired immunity by promoting antigen-driven IgG responses. 22 An elevation in the total serum IgM has been observed and is an important diagnostic feature in PBC. However, whether increased levels of IgM exert a pathogenic or a protective role in PBC remains controversial. 23, 24 Several studies have tried to dissect the possible mechanisms underlying hyper-IgM in PBC. Our previous study demonstrated that the levels of IgM are inversely correlated with the levels of CD40L methylation in PBC, suggesting direct involvement of the CD40-CD40L interaction in the production of high amounts of IgM in PBC. 25 If this is the case, then patients with HIGM who possess mutations in the gene encoding the CD40-CD40L interaction may be particularly vulnerable to developing PBC.
The expression of the CD40 ligand by activated T cells in the liver stimulates B cells to increase the production of immunoglobulin, activates macrophages to produce IL-12, leading to a shift of T-helper cells to the Th1 phenotype and subsequent IL-2 and IFN-gamma production, and induces cholangiocytes to undergo apoptosis at an increased rate. Inhibiting the CD40 pathway in PBC may dampen the autoreactive immune response, thereby improving liver function and symptoms of the disease. Indeed, there is a molecule against CD40 currently being tested in PBC (NCT02193360).
It is important to note that the ability of infectious agents to induce autoimmune responses, particularly by molecular mimicry, has been the most widely studied mechanism responsible for the initiation of PBC. 26, 27 Most of our patients with HIGM developed recurrent infections, including ENT and pulmonary infections, oral candidiasis, uveitis and otitis. Bacterial protein molecules that are modified by environmental factors, such as chemical substances, may lead to the activation of autoreactive T cells and destruction of self-tissue, thus perpetuating the autoimmune response. 24, 28 This paradigm may be an additional explanation for the susceptibility to PBC in our HIGM cohorts.
One intriguing finding of our study is that patients with HIGM have higher levels of anti-MIT3 IgM antibodies but lower levels of IgG and IgA MIT3 antibodies than controls. In a normal immune response to infection, IgM class anti-MIT3 antibodies may appear initially, with the subsequent appearance of IgG class anti-MIT3 antibodies. 29 This elevated presence of IgM class anti-MIT3 antibodies in our HIGM patients may result from the failure of IgM to switch to IgG isotypes. Of relevance, a congenic study proposed that IgM class anti-M2 antibody (specific AMA for PBC) was detected more frequently in autoimmune cholangitis patients, whom they classified as early PBC. 30 In conclusion, the IgM class of anti-AMA antibodies was shown to be present by both ELISA and IIF in most of our HIGM patients. The presence of hallmarks of PBC, a disease in which CD40L is a key player, in an immunodeficiency disease caused by mutations in the CD40L gene is very intriguing and may suggest new avenues of investigation for understanding the immune pathogenesis of PBC. It is likely that these HIGM patients who are positive for the MIT3 autoimmune marker may eventually present with PBC during long-term follow up. Longitudinal investigation of these patients will help to determine whether this latent vulnerability to developing PBC exists.
